PLSM

Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update OMER, Israel, March 30, 2026 /PRNewswire/ – Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced financial results for the full year ended December 31, 2025. Full-Year 2025 Financial Highlights Full year revenue of $12.5 million, representing a 374% increase compared to 2024, including a one-time revenue contribution of $9.6 million related to the GE settlement discussed below. Net loss improved significantly to $5 million, compared to $10 million in 2024. $21.7 million in total liquid assets (including $7 million in cash and cash equivalents) as of December 31, 2025. Recognized approximately $9.6 million in one-time revenue in connection with a settlement agreement with GE Precision Healthcare LLC (GEHC), which resolved all outstanding disputes between the parties and concluded all related proceedings. Approximately $2.2 million was recognized as revenue from the cancellation of orders placed by GEHC for 15,000 units pursuant to the Settlement Agreement and the termination of the Component Agreement. Operational Highlights Regulatory milestone – U.S.: Secured FDA clearance for remote-use prenatal ultrasound in the United States, establishing the regulatory foundation for entry into the world's largest prenatal diagnostics market. Regulatory milestone – Europe: Received Medical Device Regulation (MDR) Conformité Européenne (CE) Certification for the Pulsenmore Early-Screening (ES) pregnancy product, authorizing commercial distribution across the European Union for single-fetus pregnancies starting at 14 weeks of gestation. Commercial milestone: Initial U.S. commercial programs validating Pulsenmore ES home-use ultrasound integration with clinical workflows ahead of broader rollout. "2025 was a transformative year for Pulsenmore as we advanced from regulatory achievement to commercial execution," said Dr. Elazar Sonnenschein, CEO and Founder of Pulsenmore. "Following our FDA De Novo authorization and Nasdaq listing, we focused on scaling our U.S. infrastructure, expanding clinical partnerships, and strengthening our operational capabilities to support long-term growth. We are seeing encouraging validation from providers and health systems who recognize the value of remote, clinician-directed ultrasou...

OMER, Israel, March 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it will release its financial results for full year 2025 on March 30, 2026 at 8:30 a.m. EST. The Company will host a conference call and webcast to discuss its financial results, business highlights, and recent progress. Conference Call & Webcast Details Date: March 30, 2026 Time: 8:30 a.m. Eastern Time/ 3:30 p.m. Israel Time Webcast: https://teams.microsoft.com/meet/3845461353556?p=fcIpXc4mErwEAqo3Ir Replay: The meeting will be recorded, and the recording will be made available following the meeting on the Company's Investor Relations website at: https://pulsenmore.com/investor_relations/ Pulsenmore's executive leadership team, including Jonathan Adereth, Chairman of the Board of Directors, Dr. Elazar Sonnenschein, Founder and Chief Executive Officer, Eran Hirsh, Chief Financial Officer, and Mira Altmark-Sofer, Vice President of Marketing, will host the call to review the Company's financial results, key strategic initiatives, and recent operational progress. About Pulsenmore Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to Pulsenmore's continued commercial momentum, clinician adoption expansion, strengthening its presence in the U.S. market following its Nasdaq listing and FDA De Novo authorization and executing on its mission t...